A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma
- Author(s)
- Keon Woo Park; Ho Sup Lee; Won-Sik Lee; Sang Min Lee; Jeong-Ok Lee; Min Kyoung Kim; Kihyun Kim; Chang-Ki Min; Jae-Yong Kwak; Sang-Byung Bae; Sung-Soo Yoon; Je-Jung Lee; Ki Hwan Kim; Seung-Hyun Nam; Yeung-Chul Mun; Hyo Jung Kim; Sung Hwa Bae; Ho-Jin Shin; Jung-Hee Lee; Joon
Seong Park; Seong Hyun Jeong; Mark Hong Lee; Yang-Soo Kim; Sung-Nam Lim; Jae Hoon Lee; Do-Yeun Cho; Young
Rok Do; Jeong-A Kim; Seong Kyu Park; Jin Seok Kim; Soo-Jeong Kim; Hawk Kim; Hyeon Gyu Yi; Joon Ho Moon; Chul Won Choi; Sung-Hyun Kim; Young-Don Joo; Hoon-Gu Kim; Byung Soo Kim; Moo-Rim Park; Moo-Kon Song; Su-Youn Kim; Myung Soo Hyun; Deog Yeon Jo
- Keimyung Author(s)
- Do, Young Rok
- Department
- Dept. of Internal Medicine (내과학)
- Journal Title
- Oncotarget
- Issued Date
- 2017
- Volume
- 8
- Issue
- 23
- Keyword
- multiple myeloma; aged; bortezomib; drug therapy; combination
- Abstract
- Bortezomib-melphalan-prednisone (VMP) showed superior efficacy versus MP as first-line treatment for transplantation-ineligible multiple myeloma (MM). This study investigated the efficacy of VMP for Korean patients with MM.
Overall, 177 MM patients received 9 cycles of VMP in this prospective, multicenter, observational study. The primary endpoint was 2-year progression-free survival (PFS).
Thirty-nine (22%) patients were aged ≥ 75 years and 83 (47.4%) patients had International Staging System stage III. A median of 5 cycles were delivered. Overall response rate (ORR) was 72.9%, and complete response (CR) rate was 20.3%. With a median follow-up of 11.9 months, median PFS was 17 months. The 2-year PFS and overall survival (OS) rates were 29.2% and 80.0%, respectively. Median OS was not reached. PFS was significantly different depending on performance status (Eastern Cooperative Oncology Group < 2 vs. ≥ 2; p = 0.0002), β2-microglobulin level (< 5.5 vs. ≥ 5.5 mg/L; p = 0.0481), and cumulative dose of bortezomib (< 35.1 vs. ≥ 35.1 mg/m2; p < 0001). The common adverse events (AEs) were in line with the well-known toxicity profiles associated with VMP.
In conclusion, VMP is a feasible and effective front-line treatment for transplant-ineligible older patients with MM in Korea. Continuing therapy with prompt adjustment of treatment according to AEs may be important to improve outcomes of elderly patients.
- Authorize & License
-
- Files in This Item:
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.